Introduction
Virtually all anticancer drugs can induce tumor cell death by apoptosis. The molecular pathways that lead from speci®c cellular damage induced by the drug to the death of the cell involve a series of aspartatespeci®c cysteine proteases referred to as caspases (Salvesen and Dixit, 1997) . These proteases are synthesized as proenzymes which are proteolytically cleaved at aspartate sites into a short and a long isoforms that combine into an active heterodimer (for review, see Cohen, 1997) . A current picture of the ®nal apoptotic pathway triggered by anticancer drugs as well as many other apoptotic stimuli involves the release from mitochondria to the cytosol of proapoptotic factors such as cytochrome c (Kluck et al., 1997; Yang et al., 1997) and the Apoptosis Inducing Factor (AIF) (Susin et al., 1996) . In the cytosol, cytochrome c combines with a molecule named Apaf-1 to activate procaspase-9 in the presence of dATP . In turn, active caspase-9 activates procaspase-3, leading to proteolysis of several speci®c targets and apoptosis (for review, see . These events are regulated by proteins of the Bcl-2 family that modulate the mitochondrial release of proapoptotic factors (Kluck et al., 1997; Yang et al., 1997; VanderHeiden et al., 1997) .
Other proteins that interfere with apoptosis triggering in response to speci®c cellular damage induced by cytotoxic drugs include those involved in cell cycle regulation (for review, see Evan et al., 1995) . For example, leukemic cells undergoing apoptosis in response to DNA damage induced by topoisomerase inhibitors demonstrate a premature activation of the p34 cdc2 kinase (Shi et al., 1994) and a transcriptional activation of the gadd153 gene (Eymin et al., 1997) . It was shown also that cyclin-dependent kinase inhibitors (CDKIs) from the Kip/Cip family could interfere with drug-induced cell death. Kip/Cip proteins, that include p21 Waf1/Cip1 , p27
Kip1 and p57
Kip2
, constitute one of the two CDKI families de®ned on sequence and functional similarities. These proteins bind to and inhibit the catalytic activity of cyclin-CDK complexes with broad preference for the cyclin E-CDK2 and cyclin A-CDK2 complexes (for review, see Sherr, 1996) . The negative eect of p21
Waf1/Cip1 on drug-induced cell death has been demonstrated both in vitro (Waldman et al., 1996; Zhang et al., 1995) and in vivo (Waldman et al., 1997) . Kip2 mice have suggested a role for this CDKI as an anti-apoptotic protein (Yan et al., 1997) . p27
Kip1 has been implicated as a drug resistance factor in tumor cells spheroids (St Croix et al., 1996) as well as in colon carcinoma cells grown as con¯uent monolayers . Because enforced p27
Kip1 downregulation by antisense oligonucleotides reduced intercellular adhesion in multicellular spheroids, modulation of cell contacts was proposed to mediate p27
Kip1 antiapoptotic activity (St Croix et al., 1996) .
Here, we show that overexpression of p27 Kip1 in leukemic cells growing in suspension delays druginduced apoptosis and cytotoxicity, indicating that neither intercellular adhesion nor adherence to extracellular matrix (Cardone et al., 1997) are necessary for p27
Kip1 to prevent cell death. We also demonstrate that p27
Kip1 overexpression prevents the activation of procaspase-2L and -3 and the mitochondrial release of cytochrome c without modifying the expression of Bcl-2 and Bcl-2-related proteins. Thus, in human leukemic cells, p27
Kip1 appears as a drug resistance factor that acts upstream of the ®nal apoptotic pathway common to many apoptotic stimuli.
Results

p27
Kip1 overexpression in U937 human leukemic cells delays apoptosis induced by various stimuli
The U937 human leukemic cells were stably transfected with a pCDNA3 vector containing the full-length human p27
Kip1 cDNA. We have selected two clones, namely 27PC1 and 27PC2, that overexpressed p27
Kip1 when compared to mock-tranfected cells (Figure 1a) . The doubling time increased from 18.6+1.6 h for mock-tranfected cells to 24.9+2.0 h for p27 Kip1 -transfected cells. Mock-transfected cells treated with 50 mM etoposide underwent DNA fragmentation, starting 3 h after the beginning of treatment (Figures 1b and 2a) . DNA fragmentation was measured by a ®lter elution assay that distinguishes apoptotic from necrotic DNA fragmentation and protein-linked (e.g. topoisomerase II-linked) from non protein-linked (e.g. apoptotic) DNA damage (Solary et al., 1993; Bertrand et al., 1995) . Apoptotic DNA fragmentation was signi®cantly delayed in 27PC1 and 27PC2 clones treated in the same conditions (Figure 1b ). These two clones were also more resistant than mock-transfected cells to apoptotic DNA fragmentation induced by camptothecin (CPT), daunorubicin (DNR), vinblastin (VBL), actinomycin D (ACT), cycloheximide (CHX) or the clone CH-11 anti-Fas agonistic antibody ( Figure  1c ). The anti-apoptotic eect of p27
Kip1 overexpression was further con®rmed in 27PC1 cells treated with 50 mM etoposide or 50 ng/ml clone CH-11 antibody by identifying morphologically apoptotic cells after Hoechst 33258 staining (Figure 2a ). Morphological changes appearance was slightly delayed compared to DNA fragmentation measured by the ®lter elution assay (Figure 1 ). Twenty-four hours after the beginning of cell treatment, about 30% of p27 Kip1 -overexpressing cells have escaped apoptosis triggered by either etoposide or anti-Fas antibodies (Figures 2a and 3) . Flow cytometry analyses further con®rmed that p27 Kip1 overexpression prevented etoposide-induced as well as Fas-mediated apoptosis in U937 cells since, after 24 h of treatment, virtually all the mock-transfected cells were in sub-G 1 whereas a signi®cant population of p27 Kip1 -transfected cells accumulated in the G 0 /G 1 phase of the cell cycle (data not shown). By the use of an MTT assay in which the cells were continuously exposed to various concentrations of etoposide for 96 h, the anti-apoptotic eect of p27
Kip1 overexpression was shown to correlate with an increased resistance of leukemic cells to etoposide-induced cytotoxicity ( Figure  2b ). Etoposide IC 50 increased from 0.1 mM in mocktransfected cells to 0.8 mM in p27 Kip1 overexpression inhibits apoptosis by preventing procaspase-3 and procaspase-2 activation
We have previously shown that etoposide-induced apoptosis of U937 cells was associated with the ) and the two overexpressing-p27
Kip1 clones, 27PC1 ( ) and 27PC2 ( ), were treated with 50 mM etoposide for indicated times. Apoptotic DNA fragmentation was measured by the use of a ®lter elution assay. Results are the mean+s.d. of three independent experiments performed in triplicate. (c) Mock-transfected ( ), 27PC1 ( ) and 27PC2 ( ) cell clones were treated for 6 h with 10 mM camptothecin (CPT), 5 mM daunorubicin (DNR), 50 mg/ml cycloheximide (CHX), 10 mg/ml actinomycin D (ACT) or for 24 h with 50 ng/ml clone CH-11 anti-Fas mAb in the presence of 0.8 mg/ml CHX with 10 ng/ml vinblastin (VBL). Apoptotic DNA fragmentation was measured by the use of a ®lter elution assay. Results are the mean+s.d. of three independent experiments performed in triplicate. (*P50.05, **P50.01, ***P50.001 by Student t-test) activation of procaspase-3 (Dubrez et al., 1996) and the long isoform of procaspase-2 . Accordingly, treatment of mock-transfected U937 cells with 50 mM etoposide induces a progressive decrease in the expression of both procaspase-3 and the long isoform of procaspase-2 (procaspase-2L), starting 3 h after the beginning of cell treatment ( Figure 4a ). As previously described , this treatment also induced the accumulation of the short isoform of procaspase-2 (procaspase-2S). When U937 cells overexpressing p27
Kip1 were treated in similar conditions, both procaspase-3 and procaspase-2L remained highly expressed in the cells 24 h after the beginning of cell treatment ( Figure 4a ). Activation of caspase-3 involves its cleavage in a p20 and a p12 fragments, then the cleavage of the p20 into a p17 fragment that heterodimerizes with the p12 subunit to form the active caspase (Han et al., 1997) . Using a polyclonal antibody that identi®es the p20 and the p17 fragments of caspase-3, we observed that these fragments appeared later and with a lower intensity in p27 Kip1 -overexpressing cells compared to mock-transfected cells (Figure 4a ). Twenty-four hours after the beginning of cell treatment, these fragments were no more detectable in the fraction of p27 Kip1 -transfected cells that remained alive, suggesting that caspase-3 is no more activated in these cells. A this time point, virtually all the mock transfected cells were dead, suggesting that a fraction of p27
Kip1
-overexpressing cells might survive to the DNA damage induced by the drug. Similar results were obtained after treatment of 27PC1 with the clone CH-11 anti-Fas mAb (data not shown). To con®rm these observations, we measured caspase-3-like activity in etoposide-treated cells by the use of the DEVD-pNā uorescent substrate. p27 Kip1 -overexpression significantly decreased etoposide-induced caspase-3-like activity as compared to mock-transfected cells ( Figure  4b ).
p27
Kip1 overexpression delays mitochondrial changes associated with apoptosis Apoptosis has been shown to trigger mitochondrial permeability transition (Susin et al., 1997) as well as mitochondrial release of pro-apoptotic factors (Susin et al., 1996; Kluck et al., 1997; Yang et al., 1997) . To detect the modi®cations of the mitochondrial membrane potential, we treated mock-transfected and p27
Kip1 -overexpressing cells with 50 mM etoposide for indicated times. Then, leukemic cells were stained by using the potential-sensitive dye DiOC 6 (3). The protonophore mClCCP was used as a positive control. In mock-transfected cells, a decreased accumulation of DiOC 6 (3) was observed 30 min after the beginning of treatment (Figure 5a ). This mitochondrial change was almost completely inhibited in p27
Kip1 delays morphological changes associated with apoptosis and induces resistance to etoposide-induced cytotoxicity. (a) Mock-transfected ( ) and 27PC1 ( ) cell clones were treated with 50 mM etoposide or 50 ng/ml of the clone CH-11 anti-Fas mAb in the presence of 0.8 mg/ml cycloheximide for indicated times before Hoechst staining. The percentages of apoptotic cells were determined by counting 300 cells. (b) Cytotoxicity of etoposide was determined by using a 96 h MTT assay in mock-(*) and p27
Kip1 -transfected cells (*). Results are the mean+s.d. of three independent experiments performed in triplicate
Kip1 delays morphological changes associated with apoptosis. Mock-transfected (Mock) and p27
Kip1
-overexpressing (27PC1) U937 cells were treated with 50 mM etoposide for indicated times, stained with Hoechst 33352 (10 mg/ml) and visualized by¯uroescent microscopy transfected cells, even when studied 3 h after the beginning of drug exposure (Figure 5a ). To test the ability of p27
Kip1 to prevent cytochrome c release from the mitochondria, we prepared cytosolic and mitochondrial extracts. In mock-transfected cells treated 4 h with 50 mM etoposide, we observed an accumulation of cytochrome c in the cytosol that correlated with its decreased amount in mitochondria (Figure 5b ). In p27 Kip1 -overexpressing cells, no signi®cant change in subcellular repartition of cytochrome c was identi®ed, 4 h after the beginning of etoposide treatment ( Figure  5b ).
p27
Kip1 overexpression prevents the modulation of Bcl-2 and Bcl-2-related proteins induced by etoposide exposure
The mitochondrial release of cytochrome c was demonstrated to be prevented by overexpression of Bcl-2 and Bcl-2-related anti-apoptotic proteins (Susin et al., 1996) . To determine whether the anti-apoptotic eect of p27 Kip1 could be mediated by these proteins, we compared the expression of Bcl-2, Bcl-X L and Mcl-1 proteins in mock-and p27
Kip1
-transfected U937 cells. Because the activity of these anti-apoptotic proteins can be modulated by interactions with Bcl-2-related pro-apoptotic proteins, we also analysed the expression of Bax. p27 
Discussion
The present study demonstrates the anti-apoptotic activity of p27 Kip1 in a human leukemic cell line. A role for p27
Kip1 in drug resistance has been previously demonstrated in tumor cells grown as con¯uent monolayers or multicellular spheroids (St Croix et al., 1996; Dimanche-Boitrel et al., 1998) . Enforced p27 Kip1 downregulation by antisense oligonucleotides was shown to reduce intercellular adhesion in multicellular spheroids (St Croix et al., 1996) . Since extracellular matrix and cell contacts regulate apoptosis through an integrin-dependent negative regulation of caspases (Cardone et al., 1997; Boudreau et al., 1995) , it has been proposed that modulation of intercellular adhesion was involved in p27 Kip1 anti-apoptotic activity (St Croix et al., 1996) . The ability of p27 Kip1 to interfere with drug-induced apoptotic pathways in leukemic cells growing in suspension indicates that modulation of cellular adhesion and intercellular contacts is not required for its anti-apoptotic eect. The speci®c DNA damage induced by etoposide have not been compared in parental and p27
Kip1
-overexpressing cells. As p27 Kip1 overexpression also delays apoptosis induced by agents that do not induce DNA damage, modulation of these damage, if any, might not be the only event that explain p27 Kip1 eects on etoposide-induced cell death.
Adenovirus-mediated transient overexpression of p27
Kip1 was demonstrated recently to induce apoptosis in transfected cells (Craig et al., 1997; Katayose et al., 1997; Wang et al., 1997) . The high amount of p27 Kip1 generated by adenovirus-mediated transfection could account for this apoptotic eect of p27 Kip1 overexpression, as previously described for p21
Waf1/Cip1 (Pan et al., 1995; Duttaroy et al., 1997) . Cells arrested in G 1 were resistant to p27 Kip1 -induced cell death, suggesting that apoptosis observed in other phases of the cell cycle might result from incompatible signals between proliferation and cell cycle arrest rather than a specific pro-apoptotic activity of p27 Kip1 . In the present study, U937 cells overexpressing p27
Kip1 that survive to druginduced and Fas mediated cell death accumulate in the G 1 phase of the cell-cycle, suggesting a role for the CDK inhibitory eect of this protein in its antiapoptotic activity. Accordingly, the anti-apoptotic eect of p21
Waf1/Cip1 in cells exposed to DNA damaging agents requires its CDK-inhitory activity (Gorospe et al., 1996; Attard et al., 1996; Lu et al., 1998) whereas caspase-mediated cleavage of p21
Waf1/Cip1 observed in endothelial cells undergoing apoptosis might be instrumental in the death process by activating CDK2 (Levkau et al., 1998) . Which caspase(s) is responsible for each biochemical and morphological change associated with apoptosis is only partly understood. Caspase-3 and caspase-6 control nuclear changes associated with cell death whereas one or several distinct caspase(s) could mediate the mitochondrial permeability transition and the shrinkage of the cytoplasm (Hirata et al., 1998) . We have previously demonstrated the central role of a caspase sensitive to the DEVD tetrapeptide inhibitor in mediating etoposide-and Fas-induced cell death (Dubrez et al., 1996) . One of the caspases which are sensitive to this tetrapeptide is procaspase-3 (Nicholson et al., 1995) , a cytosolic protein that is cleaved into a 17kDa active subunit in U937 cells undergoing cell death. We have also demonstrated that expression of the long isoform of procaspase-2 decreases in U937 cells undergoing apoptosis, suggesting its cleavage into active fragments . It remains unclear whether this activation of procaspase-2 occurs upstream of caspase-3, through interactions with RAIDD and RIP proteins (Duan et al., 1997) , downstream of caspase-3, as a target for this or other downstream caspases or in parallel with caspase-3 within a branched cascade (Hirata et al., 1998) . Whatever the place of caspase-2 and caspase-3 in the proteolytic cascade triggered by etoposide, their activation is prevented by p27
Kip1 overexpression. Many of the biochemical perturbations involved in apoptosis could result from alterations in mitochondrial functions (for review, see Reed, 1997) . Mitochondrial permeability transition was proposed to trigger the release of at least two resident mitochondrial proteins, cytochrome c and apoptosis-inducing factor, that in turn activate a caspase cascade (Liu et al., 1996; Susin et al., 1996) . Another pathway was proposed in which cytochrome c released from mitochondria early in the death process activates caspases that, in turn, induce the mitochondrial permeability transition (Kluck et al., 1997; Yang et al., 1997; Susin et al., 1997; VanderHeiden et al., 1997) . Whatever the sequence of events, the ability of p27
Kip1 to inhibit both cytochrome c release and mitochondrial potential decrease indicates that this protein interferes with early steps of the apoptotic process.
Bcl-2 and several Bcl-2-related proteins such as Mcl-1 and Bcl-X L were suggested to inhibit apoptosis by preventing cytochrome c release from mitochondria (Kluck et al., 1997; Yang et al., 1997; Wang et al., 1997) whereas pro-apoptotic members of this protein family such as Bax might cause death by direct mitochondrial eects (RosseÂ et al., 1998) . We did not observe any relationship between Bcl-2, Bcl-X L , Mcl-1 and Bax protein levels in p27 Kip1 -transfected cells and their decreased sensitivity to apoptotic stimuli. p27
Kip1 overexpression prevented Mcl-1 and Bax protein level decrease associated with etoposide-induced apoptosis. Whether this inhibition is a non speci®c consequence of upstream inhibition of the death pathway triggered by the drug or a speci®c consequence of p27
Kip1 overexpression remains to be determined. To further analyse the relationships between p27
Kip1 overexpression and Mcl-1, we used another p27
Kip1 -transfected cell line. In HT29 cells, etoposide induced a time-dependent decrease of Bcl-x L , that was delayed by p27 Kip1 -overexpression, whereas Mcl-1 expression remained unchanged. These observations indicate that etoposide-induced apoptosis can be associated with the decreased expression of a Bcl-2-related protein.
Whatever the protein involved, that could depend on the cell system, p27
Kip1 overexpression interferes with the apoptotic pathway triggered by the drug upstream of the events that lead to this decreased expression. As Bcl-2-related proteins constitute a growing family of apoptosis-regulatory gene products that behave as either death antagonists or death agonists, we cannot rule out a role for other Bcl-2 family members in p27 Kip1 -mediated inhibition of cytochrome c release and cell death.
In conclusion, our results implicate p27 Kip1 as a resistance factor to drug-induced and Fas-mediated apoptosis. Furthermore, we show that p27
Kip1 acts early in the cascade leading to cell death by blocking apoptosis upstream of the ®nal common pathway that involves mitochondrial release of cytochrome c under the control of Bcl-2-related proteins and caspase activation.
Material and methods
Cell lines and culture
The human leukemic cell lines U937 (monocytic) was grown in suspension in RPMI-1640 medium (Biowhittaker, Fontenay-sous-bois, France) supplemented with 10% (v/v) heat-inactived FCS and 2 mM L-glutamine in an atmosphere of 95% air and 5% CO 2 at 378C. The human colon carcinoma cell line HT29 was cultured in Eagle Minimum Essential Medium complemented as above. Cell viability was determined using the trypan blue exclusion test. To ensure an exponential growth, cells were resuspended in fresh medium 24 h before each treatment. For detection of apoptotic cells, cells were stained with Hoechst 33352 (10 mg/ml) for 30 min at 378C before¯uorescence microscopy analysis. Apoptotic cells were identi®ed by their fragmented chromatin. Cytotoxic assays were performed using an MTT assay as previously described (Eymin et al., 1995) . Cells were continuously exposed to indicated concentrations of the drug for 96 h. Then, surviving cells were detected based on their ability to metabolize 4,5-dimethylthiazol-2,5-diphenyl tetrazolium bromide into formazan cristals. Cell survival was calculated as the fraction of cell alive relative to control for each point as cell survival (%)=mean absorbance in treated wells/mean absorbance in control wells6100. Concentrations inducing a 50% inhibition of cell growth (IC 50 ) were determined graphically from each experiment. Results are the mean (+s.d.) of three dierent experiments.
Drugs and chemical reagents
Drug stock solutions of etoposide (VP16; 50 mM), daunorubicin (DNR; 1 mg/ml), campthotecin (50 mM), cisplatin (1 mg/ml), cycloheximide (10 mg/ml), actinomycin D (5 mg/ml) and vinblastin (1 mg/ml) in dimethylsulfoxide (DMSO) were stored at 7208C. All these compounds were purchased from Sigma (Saint Quentin Fallavier, France). Further dilutions were made in culture medium just before use. Anti-human Fas mAb (IgM, clone CH-11) was obtained from Biovalley (Medical and Biological Laboratories, Conches, France) . In all experiments, the ®nal concentration of DMSO did not exceed 1% (v/v), a concentration which was non toxic to the cells.
Quanti®cation of DNA fragmentation
DNA fragmentation was measured using a previously reported ®lter elution assay (Solary et al., 1993; Bertrand et al., 1995) . Brie¯y, exponentially growing cells were incubated with 0.02 mCi/ml of [2-
14 C]thymidine (Amersham, Les Ulis, France) and cultured at 378C for 2 days. Then, cells were chased in isotope-free medium overnight, resuspended in fresh medium and treated with dierents cytotoxic drugs. Trypan blue exclusion was used to check the integrity of the plasma membrane. Then, approximately 1.0610 6 treated or untreated labeled cells were loaded onto a protein absorbing ®lter (Polyvinylidenē uorure ®lters, 0.65 mm pore size, 25 mm diameter; Durapore membrane, Millipore). Cells were then washed once with ice-cold phosphate-buered saline (PBS) and subsequently lysed in 0.2% sodium sarkosyl, 2 mol/l NaCl, 0.04 mol/l EDTA, pH 10.0. Filters were washed with 0.02 mol/l EDTA, pH 10.0. DNA was depurinated by incubation of ®lters in 1 mol/l HCl at 658C for 45 min, then released from the ®lters with 0.4 mol/l NaOH for 45 min at room temperature. Radioactivity was counted by liquid scintillation spectrometry in each fraction (wash, lysis, EDTA wash and ®lter). DNA fragmentation was determined as the percentage of disintegrations per min (d.p.m.) in the lysis+wash fractions (apoptotic fragmented DNA) divided by the lysis+wash+®lter fractions (fragmented+unfragmented DNA). The student t-test was used for statistical analyses.
Cell transfection
The full length p27
Kip1 cDNA was cloned from U937 cells by reverse-transcription polymerase chain reaction. To generate the stably transfected U937 or HT29 clones, 5610 6 cells were electroporated with 20 mg of each plasmid including empty pCDNA3 (Biovalley, Conches, France) and pCDNA3 encoding the full length p27
Kip1 . Electroporated cells were plated 48 h after electroporation in 96-well plates at dierent cell densities and selected during 4 weeks in RPMI-1640 with 10% FCS and 2 mM L-glutamine in the presence of 1 mg/ml geneticin (G418). After selection, to ensure a stable transfection, each clone was grown in RPMI-1640 containing 1 mg/ml G418.
Antibodies
Monoclonal antibodies (mAbs) used included anti-human procaspase-3, procaspase-2 (which recognizes the both isoforms procaspase-2L and procaspase-2S) and p27
Kip1
(clone 57) mAb from Transduction Laboratories (Lexington, KY, USA), anti-human cytochrome c from Pharmingen (San Diego, CA, USA), and anti-human Hsp70 mAbs from StressGen (Victoria, Canada). A polyclonal rabbit anti-apopain antiserum (kindly provided by Dr D Nicholson, Merck, Toronto, Canada), which recognizes both CPP32 proenzyme (procaspase-3) and its p20 and p17 subunits was used to detect procaspase-3 activation in apoptotic cells. To detect the proteins of Bcl-2 family, antihuman Bax mAb from Immunotech (Marseille, France), anti-human Bcl-2 and Bcl-x L mAbs from Dako (Trappes, France) and anti-human Mcl-1 rabbit polyclonal antibody from Santa-Cruz (Santa-Cruz, California, CA, USA) were used.
Western blot analysis
After treatment, cells were washed twice in PBS, lysed in RIPA buer (150 mmol/l NaCl, 50 mmol/l Tris-HCl, pH 8.0, 0.1% Na-SDS, 0.5% Na-desoxycholate) in the presence of protease inhibitors (0.1 mmol/l PmsF, 2.5 mg/ ml pepstatin, 10 g/ml aprotinin, 2.5 m/ml trypsine inhibitor, 5 mg/ml leupeptin) for 30 min, then centrifugated (20 min, 15 000 g). Fifty mg proteins of supernatants were incubated in loading buer (125 mmol/l Tris-HCl, pH 6.8, 10% bmercapto-ethanol, 4.6% SDS, 20% glycerol and 0.003% bromophenol blue), separated by 12% sodium dodecyl sulfate polyacrylamide gel (SDS ± PAGE) and electroblotted to PVDF membrane (BioRad, Ivry sur Seine, France). After blocking non-speci®c binding sites overnight with 5% nonfat milk in TPBS (PBS, Tween 20 0.1%), the membrane was incubated for 2 ± 3 h at room temperature with primary antibody. After two washes in TPBS, the membrane was incubated with horseradish peroxidaseconjugated goat anti-mouse or anti-rabbit antibodies (Jackson ImmunResearch Laboratories, West Grove, PE, USA) for 30 min at room temperature. Immunoblots were revealed using enhanced chemioluminescence detection kit (Amersham, Les Ulis, France) by autoradiography.
Measurement of caspase-3-like activity
5610
5 U937 cells were plated in 24-wells plate in 2 ml RPMI-1640 containing 10% FCS. Following treatment, cells were washed once in PBS and lysed 10 min at 48C in 50 ml lysis buer according to the protocol's instructions (ApoAlert TM CPP32/caspase-3 colorimetric assay kit, Clontech, Montigny Le Bretonneux, France). Then, 50 ml reaction buer and 5 ml of DEVD-pNA substrate were added and the reaction was incubated at 378C for 1 h in a 96-multiwell plate before colorimetric detection at 405 nm.
Preparation of cytosolic and mitochondrial extracts
Mitochondrial and cytosolic (S100) fractions for cytochome c release studies were prepared by resuspending untreated and treated cells in ice cold buer A (250 mmol/l sucrose, 20 mmol/l HEPES, 10 mmol/l KCl, 1.5 mmol/l MgCl 2 , 1 mmol/l EDTA, 1 mmol/l EGTA, 1 mmol/l DTT, 17 mg/ml PmsF, 8 mg/ml aprotinin, 2 mg/ml leupeptine (pH 7.4)) before passing them through an ice-cold dounce cell homogenizer. Unlysed cells and nuclei were pelleted via a 10 min 750 g spin. The supernatant was centrifugated at 10 000 g for 25 min, and the resulting mitochondria pellet was resuspended in buer A and frozen at 7808C. The supernatant of the 10 000 g spin was further centrifugated at 100 000 g for 1 h and the resulting supernatant (S100 fraction) which corresponds to cytosolic fraction was frozen at 7808C until analysis by immunoblotting using an anti-human cytochrome c mAb (Pharmingen, San Diego, CA, USA).
Analysis of mitochondrial membrane potential
Mock-and p27
Kip1 -transfected cells (10 6 /ml), either untreated or treated with 50 mM etoposide for indicated times were washed in ice-cold PBS, then incubated 15 min at 378C in the presence of the cationic lipophilic dye DiOC 6 (3) (40 nM in PBS; Sigma, St Quantin Fallavier, France) in dark. As a positive control, cells were simultaneously treated 30 min with the uncoupling agent carbonyl cyanide m-chlorophenylhydrazone (mClCCP; 10 mM; Sigma). Analysis was performed by the use of a FACscan cytometer (Beckton-Dickinson).
